For New RSV Shots, ‘Vaccine Fatigue’ Could Be One Of The Biggest Barriers
Executive Summary
Pfizer and GSK are expected to gain approval and launch in time for this year’s flu season, but must educate public and physicians
You may also be interested in...
GSK And Pfizer RSV Vaccines Get US Recommendation – But Big Decisions On Pricing Yet To Come
GSK and Pfizer have both raised their price ranges based on longer-term efficacy data for their RSV vaccines, but Pfizer may choose to undercut on price in order to win market share against its rival’s more favorable data.
Pfizer Anticipates A 'Bolus Of Revenue' From RSV, Prevnar 20 Launches This Year
Biopharmaceuticals president Angela Hwang said the company is anticipating a strong fourth quarter, driven by the launch of an RSV vaccine and expansion of Prevnar 20 for pediatric use.
FDA Panel Agrees GSK’s RSV Vaccine Is Effective But Wants More Data Before Approval
Advisory committee votes 10-2 that data are adequate to support safety of the vaccine in adults 60 and older, voicing concern about small potential safety signals after co-administration with influenza shot. Several members question rush to market with just one season of data.